A conversation with Geoffrey T. Sanzenbacher, a research fellow at the Center for Retirement Research.
|Articles|November 7, 2022
BGB Group Appoints Fred Bennett As Chief Digital Officer
Advertisement
BGB group, a healthcare advertising, medical education, and strategic consulting agency, announced that Fred Bennett has been named as the firm’s first-ever Chief Digital Officer (CDO).
In his role, Fred will focus on leading and managing the digital teams within BGB Group and strengthening the agency’s long-term plan for leveraging new technologies, innovation, and customer insights to meet client needs in the healthcare industry. Reporting to the agency’s Managing Partners, the CDO will be a key member of the BGB Group executive team.
Continue reading
Advertisement
Related to this article
Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.
Fox Rothschild's Mark Wagner on why the FDA counts 70 drugs in shortage while ASHP counts 188 — and what's driving the gap.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
Viatris Acquires Pacira BioSciences for $1.65 Billion
4
Pharmaceutical Executive Daily: FDA Approves Tecentriq
5